Novel Players in the Development of Chemoresistance in Ovarian Cancer: Ovarian Cancer Stem Cells, Non-coding RNA and Nuclear Receptors

Overview

Journal Cancer Drug Resist

Date 2024 Mar 4

PMID 38434767

Authors

Shahil Alam

Pankaj Kumar Giri

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) ranks as the fifth leading factor for female mortality globally, with a substantial burden of new cases and mortality recorded annually. Survival rates vary significantly based on the stage of diagnosis, with advanced stages posing significant challenges to treatment. OC is primarily categorized as epithelial, constituting approximately 90% of cases, and correct staging is essential for tailored treatment. The debulking followed by chemotherapy is the prevailing treatment, involving platinum-based drugs in combination with taxanes. However, the efficacy of chemotherapy is hindered by the development of chemoresistance, both acquired during treatment (acquired chemoresistance) and intrinsic to the patient (intrinsic chemoresistance). The emergence of chemoresistance leads to increased mortality rates, with many advanced patients experiencing disease relapse shortly after initial treatment. This review delves into the multifactorial nature of chemoresistance in OC, addressing mechanisms involving transport systems, apoptosis, DNA repair, and ovarian cancer stem cells (OCSCs). While previous research has identified genes associated with these mechanisms, the regulatory roles of non-coding RNA (ncRNA) and nuclear receptors in modulating gene expression to confer chemoresistance have remained poorly understood and underexplored. This comprehensive review aims to shed light on the genes linked to different chemoresistance mechanisms in OC and their intricate regulation by ncRNA and nuclear receptors. Specifically, we examine how these molecular players influence the chemoresistance mechanism. By exploring the interplay between these factors and gene expression regulation, this review seeks to provide a comprehensive mechanism driving chemoresistance in OC.

References

An J, Lv W, Zhang Y . LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017; 10:5377-5390. PMC: 5691924. DOI: 10.2147/OTT.S147586. View

Bai L, Wang A, Zhang Y, Xu X, Zhang X . Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 2018; 366(2):161-171. DOI: 10.1016/j.yexcr.2018.03.014. View

Xiao S, Zhang M, Liu C, Wang D . MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Mol Genet Genomics. 2018; 293(5):1159-1167. DOI: 10.1007/s00438-018-1447-0. View

He M, Wu H, Jiang Q, Liu Y, Han L, Yan Y . Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Mol Oncol. 2018; 13(2):403-421. PMC: 6360369. DOI: 10.1002/1878-0261.12419. View

Li H, Zhang W, Niu C, Lin C, Wu X, Jian Y . Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway. Int J Cancer. 2019; 145(7):1921-1934. PMC: 6767785. DOI: 10.1002/ijc.32293. View

Hu X, Meng Y, Xu L, Qiu L, Wei M, Su D . Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3. Cell Death Dis. 2019; 10(2):104. PMC: 6362125. DOI: 10.1038/s41419-018-1200-y. View

Ozes A, Miller D, Ozes O, Fang F, Liu Y, Matei D . NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 2016; 35(41):5350-5361. PMC: 5050052. DOI: 10.1038/onc.2016.75. View

Sun N, Kohli A, Huang S, Chang T, Chao C . Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells. J Cell Physiol. 2018; 234(6):8760-8775. DOI: 10.1002/jcp.27535. View

Sun C, Li N, Yang Z, Zhou B, He Y, Weng D . miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013; 105(22):1750-8. DOI: 10.1093/jnci/djt302. View

10.

Varier L, Sundaram S, Gamit N, Warrier S . An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4. Cancers (Basel). 2023; 15(4). PMC: 9954718. DOI: 10.3390/cancers15041275. View

11.

Kumar V, Vashishta M, Kong L, Wu X, Lu J, Guha C . The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol. 2021; 9:650772. PMC: 8100510. DOI: 10.3389/fcell.2021.650772. View

12.

He Y, Alejo S, Pitta Venkata P, Johnson J, Loeffel I, Pratap U . Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist. Int J Mol Sci. 2022; 23(13). PMC: 9266546. DOI: 10.3390/ijms23137159. View

13.

Le P, Romano G, Nana-Sinkam P, Acunzo M . Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. Cancers (Basel). 2021; 13(6). PMC: 8003033. DOI: 10.3390/cancers13061372. View

14.

Holzer A, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R . The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004; 66(4):817-23. DOI: 10.1124/mol.104.001198. View

15.

Wang S, Li Z, Zhu G, Hong L, Hu C, Wang K . RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. J Ovarian Res. 2021; 14(1):154. PMC: 8590297. DOI: 10.1186/s13048-021-00917-7. View

16.

Wambecke A, Ahmad M, Morice P, Lambert B, Weiswald L, Vernon M . The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels. Mol Oncol. 2021; 15(12):3659-3678. PMC: 8637575. DOI: 10.1002/1878-0261.13045. View

17.

Tian H, Yan L, Xiao-Fei L, Hai-Yan S, Juan C, Shan K . Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer. Clin Epigenetics. 2019; 11(1):153. PMC: 6822346. DOI: 10.1186/s13148-019-0748-4. View

18.

Seo E, Kim D, Jang I, Choi E, Shin S, Lee S . Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer. Oncotarget. 2016; 7(34):55624-55638. PMC: 5342441. DOI: 10.18632/oncotarget.10954. View

19.

Wang W, Fang F, Ozes A, Nephew K . Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation. Mol Cancer Ther. 2021; 20(6):1092-1101. PMC: 8172444. DOI: 10.1158/1535-7163.MCT-20-0826. View

20.

Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X . The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018; 9(11):1103. PMC: 6207559. DOI: 10.1038/s41419-018-1148-y. View